Although sotorasib is currently only approved for the treatment of KRAS G12C-mutated NSCLC, the CodeBreaK100 study has confirmed its potential for the treatment of advanced KRAS G12C mutated PDAC with low side effects. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.